HomeClinical TopicsFDA approves Nulojix for prevention of acute rejection in kidney transplant patients

FDA approves Nulojix for prevention of acute rejection in kidney transplant patients

The U.S. Food and Drug Administration (FDA) has approved Nulojix (belatacept) for prevention of acute rejection in adult patients who have had a kidney transplant. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content